Visudyne Provides Test-Case For Medicare Coverage Of Off-Label Indications

The Centers for Medicare & Medicaid Services plans to ask investigators for unpublished information from a peer-reviewed study of QLT PhotoTherapeutic's Visudyne (verteporfin) before moving forward with its decision to expand coverage to off-label indications for age-related macular degeneration (AMD)